GM-CSF-loaded chitosan hydrogel as an immunoadjuvant enhances antigen-specific immune responses with reduced toxicity

Kyung Hee Noh, Yeong Min Park, Hyuk Soon Kim, Tae Heung Kang, Kwon Ho Song, Young Ho Lee, Yeongseon Byeon, Hat Nim Jeon, In Duk Jung, Byung Cheol Shin, Kyung-Mi Lee, Seung Yong Seong, Hee Dong Han, Tae Woo Kim

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: The application of vaccine adjuvants has been vigorously studied for a diverse range of diseases in order to improve immune responses and reduce toxicity. However, most adjuvants have limited uses in clinical practice due to their toxicity. Methods: Therefore, to reduce health risks associated with the use of such adjuvants, we developed an advanced non-toxic adjuvant utilizing biodegradable chitosan hydrogel (CH-HG) containing ovalbumin (OVA) and granulocyte-macrophage colony-stimulating factor (GM-CSF) as a local antigen delivery system. Results: After subcutaneous injection into mice, OVA/GM-CSF-loaded CH-HG demonstrated improved safety and enhanced OVA-specific antibody production compared to oil-based adjuvants such as Complete Freund's adjuvant (CFA) or Incomplete Freund's adjuvant (IFA). Moreover, CH-HG system-mediated immune responses was characterized by increased number of OVA-specific CD4 and CD8 INF-γ T cells, leading to enhanced humoral and cellular immunity. Conclusions: In this study, the improved safety and enhanced immune response characteristics of our novel adjuvant system suggest the possibility of the extended use of adjuvants in clinical practice with reduced apprehension about toxic side effects.

Original languageEnglish
Article number41
JournalBMC Immunology
Volume15
Issue number1
DOIs
Publication statusPublished - 2014 Oct 18

Fingerprint

Immunologic Adjuvants
Hydrogel
Histocompatibility Antigens Class II
Ovalbumin
Chitosan
Granulocyte-Macrophage Colony-Stimulating Factor
Safety
Freund's Adjuvant
Poisons
Subcutaneous Injections
Humoral Immunity
Cellular Immunity
Antibody Formation
Immune System
Oils
Vaccines
T-Lymphocytes
Antigens
Health

Keywords

  • Adjuvant
  • Chitosan
  • Hydrogel
  • Immune response

ASJC Scopus subject areas

  • Immunology

Cite this

GM-CSF-loaded chitosan hydrogel as an immunoadjuvant enhances antigen-specific immune responses with reduced toxicity. / Noh, Kyung Hee; Park, Yeong Min; Kim, Hyuk Soon; Kang, Tae Heung; Song, Kwon Ho; Lee, Young Ho; Byeon, Yeongseon; Jeon, Hat Nim; Jung, In Duk; Shin, Byung Cheol; Lee, Kyung-Mi; Seong, Seung Yong; Han, Hee Dong; Kim, Tae Woo.

In: BMC Immunology, Vol. 15, No. 1, 41, 18.10.2014.

Research output: Contribution to journalArticle

Noh, KH, Park, YM, Kim, HS, Kang, TH, Song, KH, Lee, YH, Byeon, Y, Jeon, HN, Jung, ID, Shin, BC, Lee, K-M, Seong, SY, Han, HD & Kim, TW 2014, 'GM-CSF-loaded chitosan hydrogel as an immunoadjuvant enhances antigen-specific immune responses with reduced toxicity', BMC Immunology, vol. 15, no. 1, 41. https://doi.org/10.1186/s12865-014-0048-x
Noh, Kyung Hee ; Park, Yeong Min ; Kim, Hyuk Soon ; Kang, Tae Heung ; Song, Kwon Ho ; Lee, Young Ho ; Byeon, Yeongseon ; Jeon, Hat Nim ; Jung, In Duk ; Shin, Byung Cheol ; Lee, Kyung-Mi ; Seong, Seung Yong ; Han, Hee Dong ; Kim, Tae Woo. / GM-CSF-loaded chitosan hydrogel as an immunoadjuvant enhances antigen-specific immune responses with reduced toxicity. In: BMC Immunology. 2014 ; Vol. 15, No. 1.
@article{3006f71ed2644a07803172e7f5712df9,
title = "GM-CSF-loaded chitosan hydrogel as an immunoadjuvant enhances antigen-specific immune responses with reduced toxicity",
abstract = "Background: The application of vaccine adjuvants has been vigorously studied for a diverse range of diseases in order to improve immune responses and reduce toxicity. However, most adjuvants have limited uses in clinical practice due to their toxicity. Methods: Therefore, to reduce health risks associated with the use of such adjuvants, we developed an advanced non-toxic adjuvant utilizing biodegradable chitosan hydrogel (CH-HG) containing ovalbumin (OVA) and granulocyte-macrophage colony-stimulating factor (GM-CSF) as a local antigen delivery system. Results: After subcutaneous injection into mice, OVA/GM-CSF-loaded CH-HG demonstrated improved safety and enhanced OVA-specific antibody production compared to oil-based adjuvants such as Complete Freund's adjuvant (CFA) or Incomplete Freund's adjuvant (IFA). Moreover, CH-HG system-mediated immune responses was characterized by increased number of OVA-specific CD4 and CD8 INF-γ T cells, leading to enhanced humoral and cellular immunity. Conclusions: In this study, the improved safety and enhanced immune response characteristics of our novel adjuvant system suggest the possibility of the extended use of adjuvants in clinical practice with reduced apprehension about toxic side effects.",
keywords = "Adjuvant, Chitosan, Hydrogel, Immune response",
author = "Noh, {Kyung Hee} and Park, {Yeong Min} and Kim, {Hyuk Soon} and Kang, {Tae Heung} and Song, {Kwon Ho} and Lee, {Young Ho} and Yeongseon Byeon and Jeon, {Hat Nim} and Jung, {In Duk} and Shin, {Byung Cheol} and Kyung-Mi Lee and Seong, {Seung Yong} and Han, {Hee Dong} and Kim, {Tae Woo}",
year = "2014",
month = "10",
day = "18",
doi = "10.1186/s12865-014-0048-x",
language = "English",
volume = "15",
journal = "BMC Immunology",
issn = "1471-2172",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - GM-CSF-loaded chitosan hydrogel as an immunoadjuvant enhances antigen-specific immune responses with reduced toxicity

AU - Noh, Kyung Hee

AU - Park, Yeong Min

AU - Kim, Hyuk Soon

AU - Kang, Tae Heung

AU - Song, Kwon Ho

AU - Lee, Young Ho

AU - Byeon, Yeongseon

AU - Jeon, Hat Nim

AU - Jung, In Duk

AU - Shin, Byung Cheol

AU - Lee, Kyung-Mi

AU - Seong, Seung Yong

AU - Han, Hee Dong

AU - Kim, Tae Woo

PY - 2014/10/18

Y1 - 2014/10/18

N2 - Background: The application of vaccine adjuvants has been vigorously studied for a diverse range of diseases in order to improve immune responses and reduce toxicity. However, most adjuvants have limited uses in clinical practice due to their toxicity. Methods: Therefore, to reduce health risks associated with the use of such adjuvants, we developed an advanced non-toxic adjuvant utilizing biodegradable chitosan hydrogel (CH-HG) containing ovalbumin (OVA) and granulocyte-macrophage colony-stimulating factor (GM-CSF) as a local antigen delivery system. Results: After subcutaneous injection into mice, OVA/GM-CSF-loaded CH-HG demonstrated improved safety and enhanced OVA-specific antibody production compared to oil-based adjuvants such as Complete Freund's adjuvant (CFA) or Incomplete Freund's adjuvant (IFA). Moreover, CH-HG system-mediated immune responses was characterized by increased number of OVA-specific CD4 and CD8 INF-γ T cells, leading to enhanced humoral and cellular immunity. Conclusions: In this study, the improved safety and enhanced immune response characteristics of our novel adjuvant system suggest the possibility of the extended use of adjuvants in clinical practice with reduced apprehension about toxic side effects.

AB - Background: The application of vaccine adjuvants has been vigorously studied for a diverse range of diseases in order to improve immune responses and reduce toxicity. However, most adjuvants have limited uses in clinical practice due to their toxicity. Methods: Therefore, to reduce health risks associated with the use of such adjuvants, we developed an advanced non-toxic adjuvant utilizing biodegradable chitosan hydrogel (CH-HG) containing ovalbumin (OVA) and granulocyte-macrophage colony-stimulating factor (GM-CSF) as a local antigen delivery system. Results: After subcutaneous injection into mice, OVA/GM-CSF-loaded CH-HG demonstrated improved safety and enhanced OVA-specific antibody production compared to oil-based adjuvants such as Complete Freund's adjuvant (CFA) or Incomplete Freund's adjuvant (IFA). Moreover, CH-HG system-mediated immune responses was characterized by increased number of OVA-specific CD4 and CD8 INF-γ T cells, leading to enhanced humoral and cellular immunity. Conclusions: In this study, the improved safety and enhanced immune response characteristics of our novel adjuvant system suggest the possibility of the extended use of adjuvants in clinical practice with reduced apprehension about toxic side effects.

KW - Adjuvant

KW - Chitosan

KW - Hydrogel

KW - Immune response

UR - http://www.scopus.com/inward/record.url?scp=84923874043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923874043&partnerID=8YFLogxK

U2 - 10.1186/s12865-014-0048-x

DO - 10.1186/s12865-014-0048-x

M3 - Article

C2 - 25323934

AN - SCOPUS:84923874043

VL - 15

JO - BMC Immunology

JF - BMC Immunology

SN - 1471-2172

IS - 1

M1 - 41

ER -